---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-016867"
form_type: "8-K"
ticker: "DYAI"
cik: "0001213809"
company_name: "DYADIC INTERNATIONAL INC"
filed_at: "2025-05-14T23:59:59+00:00"
generated_at: "2026-05-21T08:01:30.411859+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Dyadic Q1 2025 revenue $394K, net loss $2.028M; cash $7.3M; progress on C1 platform grants

## Summary
- Revenue $394K, up from $335K YoY, driven by $210K in Gates Foundation and CEPI grant revenue.
- Net loss $2.028M vs $2.01M YoY; operating loss improved to $2.002M from $2.126M.
- Cash, cash equivalents and securities $7.3M at March 31, 2025, down from $9.3M at Dec 31, 2024.
- Up to $4.5M CEPI grant and $3M Gates Foundation grant advancing C1 platform for vaccines and antibodies.
- Commercial launch of recombinant Human Serum Albumin expected Q3 2025; dairy enzyme launch late 2025.

## SEC filing metadata
- accession: 0001437749-25-016867
- form_type: 8-K
- ticker: DYAI
- cik: 0001213809
- company_name: DYADIC INTERNATIONAL INC
- filed_at: 2025-05-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1213809/000143774925016867/0001437749-25-016867-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1213809/000143774925016867/dyai20250107_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-016867
- JSON: https://secwatch.observer/filing/0001437749-25-016867.json
- Plain text: https://secwatch.observer/filing/0001437749-25-016867.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.